aleniglipron
GSBR-1290 Small Molecule Target: GLP-1R, GLP-1 receptor
Structure Therapeutics
Most recent annual filing: 2026-02-26
- aleniglipron Ph2 topline3Q 2026aleniglipron Ph2 topline, 3Q 2026, major
- ACCG-2671 Ph1 readout3Q 2026ACCG-2671 Ph1 readout, 3Q 2026, material
- aleniglipron Ph3 startAug 2026aleniglipron Ph3 start, Aug 2026, notable
- ACCG-3535 / combination trial Ph14Q 2026ACCG-3535 / combination trial Ph1, 4Q 2026, notable
Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.
Pipeline (5 active programs)
Technology platforms
Structure-Based Drug Discovery Platform · Schrödinger
GPCR-focused structure-based drug discovery platform combining 3D protein structure visualization, computational chemistry, and physics-based methods in collaboration with Schrödinger. Targets GPCRs in metabolic, cardiovascular, and pulmonary diseases, enabling design of oral small molecule therapeutics against targets historically limited to peptides or biologics.
Targets: GPCRs
GPCR Structure-Based Drug Discovery
Structure-based drug discovery and computational chemistry platform focused on G-protein coupled receptors (GPCRs); targets metabolic, cardiovascular, pulmonary and neurological disorders including obesity, T2DM, MASH, heart failure, sleep apnea, chronic kidney disease, and osteoarthritis.
Targets: GIPR, GCGR, GLP-1R
Discontinued (1)
- ANPA-0073 — undisclosed · decided not suitable for selective weight loss; deprioritized in favor of other discovery stage APJ receptor agonists
Biotech Distilled coverage (3)
- 2026-08-07 UPDATE: Structure Therapeutics (GPCR) - Phase 3 Is Dosing, and the Stock Already Knows 🔒 Paid
- 2026-05-08 UPDATE: Structure Therapeutics (GPCR) - The 16.3% Print and the Quiet ATM Upsize 🔒 Paid
- 2026-04-28 Structure Therapeutics (GPCR) - Scientific Deep Dive for Aleniglipron and Pipeline Products 🔒 Paid
Articles open on Substack. Some deep dives are subscriber-only.